Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features.

Autor: Goldman JG; Section of Parkinson Disease and Movement Disorders, Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA., Andrews H; Division of Movement Disorders, Department of Neurology, Columbia University Medical Center, New York, New York, USA., Amara A; Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA., Naito A; The Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA., Alcalay RN; Division of Movement Disorders, Department of Neurology, Columbia University Medical Center, New York, New York, USA., Shaw LM; Department of Pathology & Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA, USA., Taylor P; BioLegend Inc, Dedham, USA., Xie T; Parkinson Disease and Movement Disorder Program, Department of Neurology, University of Chicago, Chicago, Illinois, USA., Tuite P; Department of Neurology, University of Minnesota, Minneapolis, Minnesota, USA., Henchcliffe C; Department of Neurology, Weill Cornell Medical College, New York, New York, USA., Hogarth P; Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon, USA., Frank S; Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, USA., Saint-Hilaire MH; Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, USA., Frasier M; The Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA., Arnedo V; The Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA., Reimer AN; The Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA., Sutherland M; National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA., Swanson-Fischer C; National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA., Gwinn K; National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA., Kang UJ; Division of Movement Disorders, Department of Neurology, Columbia University Medical Center, New York, New York, USA.
Jazyk: angličtina
Zdroj: Movement disorders : official journal of the Movement Disorder Society [Mov Disord] 2018 Feb; Vol. 33 (2), pp. 282-288. Date of Electronic Publication: 2017 Dec 04.
DOI: 10.1002/mds.27232
Abstrakt: Objective: Examine relationships among neurodegenerative biomarkers and PD motor and nonmotor symptoms.
Background: CSF alpha-synuclein is decreased in PD versus healthy controls, but whether plasma and saliva alpha-synuclein differentiate these groups is controversial. Correlations of alpha-synuclein among biofluids (CSF, plasma, saliva) or biomarkers (eg, beta-amyloid, tau [total, phosphorylated]) are not fully understood. The relationships of these biomarkers with PD clinical features remain unclear.
Methods: BioFIND, a cross-sectional, observational study, examines clinical and biomarker characteristics in moderate-advanced PD and matched healthy controls. We compared alpha-synuclein concentrations across diagnosis, biofluids, and CSF biomarkers. Correlations of CSF biomarkers and MDS-UPDRS, motor phenotype, MoCA, and rapid eye movement sleep behavior disorder questionnaire scores in PD were examined.
Results: CSF alpha-synuclein was lower in PD versus controls (P = .01), controlling for age, gender, and education. Plasma and saliva alpha-synuclein did not differ between PD and controls, and alpha-synuclein did not significantly correlate among biofluids. CSF beta-amyloid 1-42 was lower in PD versus controls (P < .01), and correlated weakly with MoCA recall scores (r = 0.23, P = .02). CSF alpha-synuclein was lower in the postural instability/gait difficulty phenotype than other motor phenotypes (P < .01). No CSF biomarkers predicted or correlated with total motor or rapid eye movement sleep behavior disorder scores. CSF alpha-synuclein correlated with beta-amyloid 1-42 , total-tau, and phosphorylated-tau (r = 0.41, 0.81, 0.43, respectively; Ps < .001).
Conclusion: Lower CSF alpha-synuclein is associated with diagnosis and motor phenotype in moderate-advanced PD. Plasma and saliva alpha-synuclein neither correlate with CSF alpha-synuclein, nor distinguish PD from controls. CSF beta-amyloid 1-42 remains a potential biomarker for cognitive impairment in PD. © 2017 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
(© 2017 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.)
Databáze: MEDLINE
Externí odkaz: